Pentagastrin

• CAT Number: I004061
• CAS Number: 5534-95-2
• Molecular Formula: C37H49N7O9S
• Molecular Weight: 767.89
• Purity: ≥95%
• Solubility: DMSO ≥ 34 mg/mL
• Storage: 3 years -20℃ powder
• IUPAC Name: (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoylamino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid
• InChI: InChI=1S/C37H49N7O9S/c1-37(2,3)53-36(52)39-16-14-30(45)41-28(19-23-21-40-25-13-9-8-12-24(23)25)34(50)42-26(15-17-54-4)33(49)44-29(20-31(46)47)35(51)43-27(32(38)48)18-22-10-6-5-7-11-22/h5-13,21,26-29,40H,14-20H2,1-4H3,(H2,38,48)(H,39,52)(H,41,45)(H,42,50)(H,43,51)(H,44,49)(H,46,47)/t26-,27-,28-,29-/m0/s1
• InChIKey: NEYNJQRKHLUJRU-DZUOILHNSA-N
• SMILES: CC(C)(C)OC(=O)NCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CC3=CC=CC=C3)C(=O)N

Pentagastrin (Cat.No:I004061) is a synthetic peptide that stimulates gastric acid secretion. It acts as a potent cholecystokinin (CCK) agonist, binding to CCK receptors in the stomach and triggering the release of gastric acid. Pentagastrin is used in diagnostic tests to evaluate gastric acid secretion and to assess gastric function in clinical settings.

Reference

1:Comparative assessment of calcitonin stimulation test using calcium gluconate and pentagastrin and the usefulness of procalcitonin basic and post-stimulation concentrations in the diagnosis of patients after surgery for medullary. Kowalska A, Lizis-Kolus K, Gąsior-Perczak D, Palyga I, Słuszniak A, Słuszniak J, Antczak G, Lizis P, Mezyk R, Gozdz S.Neuro Endocrinol Lett. 2016 Dec;37(7):485-490. PMID: 28326742 2:Esomeprazole inhibits the pentagastrin-stimulated secretion of gastric acid in healthy Japanese volunteers. Maejima R, Koike T, Nakagawa K, Iijima K, Shimosegawa T.Tohoku J Exp Med. 2015;235(3):249-53. doi: 10.1620/tjem.235.249. PMID: 25786769 Free Article3:Role of ERK-MAPK signaling pathway in pentagastrin-regulated growth of large intestinal carcinoma. Mao JD, Wu P, Huang JX, Wu J, Yang G.World J Gastroenterol. 2014 Sep 21;20(35):12542-50. doi: 10.3748/wjg.v20.i35.12542. PMID: 25253956 Free PMC Article4:Low-dose calcium versus pentagastrin for stimulation of calcitonin in chronic hemodialysis patients: a pilot study. Thiem U, Marculescu R, Cejka D, Gessl A, Borchhardt K.J Clin Endocrinol Metab. 2014 Dec;99(12):4704-11. doi: 10.1210/jc.2014-1869. PMID: 25215555 5:Comparison of side effects of pentagastrin test and calcium stimulation test in patients with increased basal calcitonin concentration: the gender-specific differences. Ubl P, Gincu T, Keilani M, Ponhold L, Crevenna R, Niederle B, Hacker M, Li S.Endocrine. 2014 Aug;46(3):549-53. doi: 10.1007/s12020-013-0109-6. Epub 2013 Nov 23. PMID: 24272596 6:Use of the pentagastrin dog model to explore the food effects on formulations in early drug development. Zane P, Guo Z, MacGerorge D, Vicat P, Ollier C.Eur J Pharm Sci. 2014 Jun 16;57:207-13. doi: 10.1016/j.ejps.2013.09.018. Epub 2013 Oct 1. PMID: 24090732 7:Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects. Boyce M, Warrington S, Black J.Br J Clin Pharmacol. 2013 Nov;76(5):689-98. doi: 10.1111/bcp.12099. PMID: 23432534 Free PMC Article8:Hypercalcitoninemia in thyroid conditions other than medullary thyroid carcinoma: a comparative analysis of calcium and pentagastrin stimulation of serum calcitonin. Lorenz K, Elwerr M, Machens A, Abuazab M, Holzhausen HJ, Dralle H.Langenbecks Arch Surg. 2013 Mar;398(3):403-9. doi: 10.1007/s00423-013-1049-6. Epub 2013 Feb 14. PMID: 23408061 9:Failure of pentagastrin-stimulated calcitonin testing in early manifestation of familial medullary thyroid cancer. Pirich C, Rendl G, Hauser-Kronberger C, Häusler I.Wien Klin Wochenschr. 2012 Oct;124(19-20):723-4. doi: 10.1007/s00508-012-0241-y. Epub 2012 Sep 11. PMID: 22965292 10:Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test? Pina G, Dubois S, Murat A, Berger N, Niccoli P, Peix JL, Cohen R, Guillausseau C, Charrie A, Chabre O, Cornu C, Borson-Chazot F, Rohmer V; Groupe des Tumeurs Endocrines..Clin Endocrinol (Oxf). 2013 Mar;78(3):358-64. doi: 10.1111/cen.12001. PMID: 22913268